BioStem Technologies BSEM
- Market cap
- $20.7M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $16M | $11M | $6.1M | $7.9M | |
| Cost of revenue | $853.4K | $685.2K | $2.4M | $3.1M |
| Gross profit | $15.1M | $10.3M | $3.8M | $4.8M |
| R&D | $1.7M | $2M | $1.1M | $733.6K |
| SG&A | $8.1M | $8.1M | $11M | $11.8M |
| $5.2M | $112.8K | −$8.9M | −$8.4M | |
| Pre-tax income | $5.3M | $178K | −$8.8M | −$9M |
| $1.4M | $167.3K | $0 | $0 | |
| Net income | $3.9M | $10.6K | −$8.8M | −$9M |
| $0.17 | $0.00 | −$0.52 | −$0.52 | |
| 23.6M | 23.4M | 16.8M | 17.3M |
Revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
R&D: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
SG&A: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Operating income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Income tax: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
Net income: Q1 FY25 and Q1 FY26: 6 months less the 3 months printed beside them.
EPS, diluted: Q1 FY25 and Q1 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY25 and Q1 FY26: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest BioStem Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| BSEMBioStem Technologies | $20.7M | n/m | n/a | n/m | n/m | n/m | |
| NEPHNephros | $35.2M | 20.3× | 28.3× | 1.7× | +24% | 8.4% | |
| ATNMActinium Pharmaceuticals | $45M | 4.0× | 3.3× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.3M | 13.5× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $60.6M | 9.5× | 9.5× | 1.3× | −3% | 15.7% | |
| LFVNLifevantage | $73.5M | 14.7× | 19.4× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $95.9M | 132× | 44.1× | 3.1× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| PLXProtalix BioTherapeutics | $206.3M | 11.1× | 33.6× | 2.6× | +30% | 23.5% | |
| Peer median | $73.5M | 13.5× | 16.5× | 1.5× | +7% | 7.6% |
More on BioStem Technologies
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .